BioSpace News Archive

Immunic, Inc. announced financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Bio-Path Holdings, Inc. announced that it will host a live conference call and audio webcast on Wednesday, May 15, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024 and to provide a business overview.

Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, announced its financial results for the first quarter ended March 31, 2024 and provided a business update.

Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements and management disclosure and analysis for its second quarter of fiscal 2024 ended March 31, 2024 prior to the start of trading on May 15, 2024.

SpringWorks Therapeutics, Inc. announced that management will participate in a fireside chat at the BofA Securities 2024 Health Care Conference, taking place in Las Vegas, Nevada on Tuesday, May 14, 2024 at 3:40 p.m. PT / 6:40 p.m. ET.

Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, announced the acquisition of Serendipity Biosciences, a private biotechnology company focused on the discovery of unique gene editing technologies.

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, provided a corporate update and announced its financial results for the quarter ended March 31, 2024.

Omega Therapeutics, Inc. announced the presentation of new preclinical data demonstrating durable and tunable bidirectional regulation of gene expression in cellular models at the pre-transcriptional level at the American Society of Gene and Cell Therapy 27th Annual Meeting, taking place in Baltimore, Maryland, May 7 – 11.

Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced its financial results for the three months ended March 31, 2024, and provided a clinical and business update.

Aura Biosciences, Inc. announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: